George W. Lemaitre Sells 68,906 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the sale, the chief executive officer now owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The sale was disclosed in a legal filing with the SEC, which is available at this link.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $76.00 on Friday. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $76.24. The business’s fifty day moving average is $66.67 and its 200 day moving average is $59.46. The stock has a market capitalization of $1.71 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The firm had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. During the same quarter last year, the firm posted $0.27 EPS. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be paid a dividend of $0.16 per share. The ex-dividend date is Wednesday, May 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.84%. LeMaitre Vascular’s dividend payout ratio is presently 42.38%.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and upped their price target for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Barrington Research increased their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. JMP Securities lifted their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research report on Friday, May 3rd. StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Finally, KeyCorp assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, February 6th. They issued a “sector weight” rating for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $73.83.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently modified their holdings of the company. Mesirow Institutional Investment Management Inc. purchased a new stake in LeMaitre Vascular during the fourth quarter valued at $8,837,000. Congress Asset Management Co. MA grew its stake in shares of LeMaitre Vascular by 36.3% during the 3rd quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock valued at $27,696,000 after purchasing an additional 135,266 shares during the period. Ranger Investment Management L.P. increased its position in shares of LeMaitre Vascular by 15.8% during the 3rd quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock valued at $48,968,000 after purchasing an additional 122,601 shares during the last quarter. Summit Creek Advisors LLC lifted its stake in shares of LeMaitre Vascular by 37.8% in the 4th quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock worth $12,970,000 after purchasing an additional 62,737 shares during the period. Finally, Conestoga Capital Advisors LLC boosted its holdings in shares of LeMaitre Vascular by 3.0% in the third quarter. Conestoga Capital Advisors LLC now owns 1,917,581 shares of the medical instruments supplier’s stock worth $104,470,000 after buying an additional 55,895 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.